The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000886381p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
14/06/2026
Date registered
Help: Date registered
17/07/2026
Date last updated
Help: Date last updated
17/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Clinical trial investigating the effect of tongkat ali (Physta) on anabolic hormone markers, body composition and muscular strength in middle-aged males.
Scientific title
Effects of Tongkat Ali (Physta) Supplementation on Anabolic Hormone Markers, Body Composition, and Muscular Strength in Middle-Aged Men: A Randomized Clinical Trial
Additional trial identifiers [1] 316664 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Reduced testosterone levels in middle-aged males 342794 0
Condition category
Condition code
Metabolic and Endocrine 337055 337055 0 0
Normal metabolism and endocrine development and function

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study will use an 13-week double-blind, placebo-controlled, repeated measures parallel design. Participants will be randomised to receive either Physta® or placebo.

Following baseline measurements in week 1, the study will have two phases. Phase one will be a lead in period of three weeks (week 2-4) where participants will start their supplementation protocol and take either the intervention supplement or placebo. Following this period, phase two (weeks 5-12) is when participants will continue with the supplementation protocol and begin the eight-week strength training intervention.

Study participants will be randomised (double blind) to either receive 400mg/day of Physta or a placebo over an 11 week period. These will be in tablet form and taken orally. Participant compliance with supplement and strength training intervention will be assessed through a combination of monitoring by the lead researcher through weekly online check-ins through group chat methods using suitable apps (WhatsApp) and through group and personal email communication. Participants who report not being compliant with the supplementation protocol will be reminded of their obligation regarding appropriate study compliance. Study participants will be asked to record any missed supplementation intake in the Supplement Compliance Diary and return any unused supplements at the end of the study where pill counts will be carried out. The lead researcher will review diaries at the end of the study to verify adherence and reconcile discrepancies between diary entries and pill counts.

The study will be carried out at the University of Canberra and the strength training intervention at the Fit and Well fitness centre at the Canberra Institute of Technology (CIT).

Following the phase one period (week 2 - 4) all study participants will commence an eight week strength training program. The intervention and placebo group will complete the same strength training program. Study participants will be allocated an Exercise Physiology student completing placement hours who will supervise them for the duration of the strength training program. These students will be supervised by the lead researcher and a qualified Exercise Physiologist at CIT Fit and Well.

The strength training program will be a four day a week program following an upper / lower body structure (training these areas two times a week). Training sessions will be in small groups (3-4 participants per student). The intensity of the strength training program will moderate to vigorous intensity (repetitions in reserve 2-3 per set) and each training session will be approximately 60 minutes. Training session adherence and completion will be monitored using a digital application developed through Replit where students will recorded each participants training session. See program structure and exercises below.

Upper Body Exercises
- Bench Press
- Pec Fly Machine
- Lat Pulldown
- Seated Row
- Machine Shoulder press
- Face pulls
- Standing DB Bicep curls
- Triceps Pushdown
- Russian Twists (loaded)

Lower Body Exercises
- Leg press
- Dumbbell Bulgarian Split Squat
- Deadlift
- Leg Extension
- Seated Leg curls
- Standing Calf Raises
- Back Extensions (loaded)

All study participants will be required to cease intake of any type of dietary or herbal supplement which may impact hormonal status at least one month before baseline testing and discontinue the intake of this supplement for the duration of the study period.

This study will be conducted by a qualified dietitian and sports dietitian, personal trainer and educator with experience spanning three decades in the areas of fitness, health and sport.
Intervention code [1] 333340 0
Lifestyle
Intervention code [2] 333341 0
Prevention
Intervention code [3] 333342 0
Treatment: Drugs
Description of the comparator or control
The control group will be given a placebo tablet with the ingredient used being maltodextrin and will be designed to look identical in colour, shape, size, and packaging.
Control group
Placebo

Outcomes
Primary outcome [1] 344562 0
Total testosterone (nmol/L)
Timepoint [1] 344562 0
Week 1, 4 and 13 (primary timepoints) post randomisation
Primary outcome [2] 344563 0
Fat free mass (kg)
Timepoint [2] 344563 0
Week 1 and 13 (primary timepoints) post randomisation
Primary outcome [3] 344564 0
1RM Leg press (kg)
Timepoint [3] 344564 0
Week 1 and 13 post randomisation
Secondary outcome [1] 458348 0
Free testosterone (pmol/L)
Timepoint [1] 458348 0
Week 1, 4 and 13 post randomisation
Secondary outcome [2] 458349 0
Luteinizing hormone (IU/L)
Timepoint [2] 458349 0
Week 1, 4 and 13 post randomisation
Secondary outcome [3] 463006 0
Follicle stimulating hormone (U/L)
Timepoint [3] 463006 0
Week 1, 4 and 13 post randomisation
Secondary outcome [4] 464712 0
Sex Binding Globulin Hormone (nmol/L)
Timepoint [4] 464712 0
Week 1,4 and 13 post randomisation
Secondary outcome [5] 464715 0
Dehydroepiandrosterone (u mol/L)
Timepoint [5] 464715 0
Week 1,4 and 13 post randomisation
Secondary outcome [6] 464716 0
Cortisol (nmol/L)
Timepoint [6] 464716 0
Week 1,4 and 13 post randomisation
Secondary outcome [7] 464718 0
Fat mass (kg)
Timepoint [7] 464718 0
Week 1 and 13 post randomisation
Secondary outcome [8] 464721 0
1RM Bench Press (kg)
Timepoint [8] 464721 0
Week 1 and 13 post randomisation
Secondary outcome [9] 464726 0
Liver function test
Timepoint [9] 464726 0
Week 1, 4 and 13 post randomisation
Secondary outcome [10] 464728 0
Electrolytes
Timepoint [10] 464728 0
Week 1, 4 and 13 post randomisation
Secondary outcome [11] 464730 0
Total blood count
Timepoint [11] 464730 0
Week 1, 4 and 13 post randomisation
Secondary outcome [12] 464811 0
High sensitivity C-Reactive Protein (hs-CRP)
Timepoint [12] 464811 0
Week 1,4 and 13 post randomisation
Secondary outcome [13] 464812 0
High Sensitivity Heat Shock Protein 70 (hs-HSP70)
Timepoint [13] 464812 0
Week 1, 4 and 13 post randomisation.
Secondary outcome [14] 465228 0
Urea
Timepoint [14] 465228 0
Week 1, 4 and 13 post randomisation.
Secondary outcome [15] 465229 0
Creatinine
Timepoint [15] 465229 0
Week 1, 4 and 13 post randomisation.

Eligibility
Key inclusion criteria
Males aged 45-55 years
Physically active and in good health
Minimum of 6 months resistance training experience
Cleared to participate in a resistance training program based on screening using the Exercise and Sport Science Australia (ESSA) Adult Pre-Exercise Screening System Tool .
Minimum age
45 Years
Maximum age
55 Years
Sex
Males
Healthy volunteers
Yes
Key exclusion criteria
Participants will be excluded if they meet any of the following criteria:
• Female or assigned female at birth.
• Outside the age range of 45-55 years
• Health conditions that contra-indicate use of TB supplement
• Taking any type of hormone therapy or medication which may impact hormone profile
• Injury or condition that contraindicates participation in resistance training. The Exercise and Sport Science Australia (ESSA) Adult Pre-Exercise Screening System Tool will be used to screen all participants for eligibility prior to commencement of the study (1).
• Are currently taking prescribed any of the following medication which my impacts total testosterone including analgesics, anaesthetics, sedatives, tranquilizers, antidepressants, stimulants, hallucinogens, cholesterol and hypertensive medication and chemotherapy
• Participate in a sport that requires compliance with World Anti-Doping Agency guidelines
These groups are excluded as they do not represent the sample cohort targeted in this trial.

1. ESSA. ESSA - Pre-Exercise Screening Systems. Pre-Exercise Screening Systems. 2024. Accessed October 20, 2024. https://www.essa.org.au/Public/Public/ABOUT_ESSA/Pre-Exercise_Screening_Systems.aspx

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone/fax/computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
An a priori power analysis (G*Power v. 3.1.5.1) indicated that 34 participants will be required. This calculation was based on a moderate effect size (Cohen’s d = 0.25), an alpha level of 0.05, a ß-value of 0.8 for a repeated measures within or between an analysis of variance (ANOVA) design with two groups and a correlation among repeated measures value of 0.5 (1)

Statistical analysis will be conducted using R statistical software. Data will be tested for normality. ‘Time’ (Pre vs Post), ‘Treatment’ (Supplement vs Placebo), and interactive (‘Time x Treatment’) effects will be analysed by two-way repeated measures ANOVA, followed by Least Significant Difference (LSD) post hoc testing if either of the omnibus F-tests are significant.

1. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191. doi:10.3758/BF03193146

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT

Funding & Sponsors
Funding source category [1] 321277 0
Commercial sector/Industry
Name [1] 321277 0
Biotropics Malaysia Berhad (Biotropics)
Country [1] 321277 0
Malaysia
Primary sponsor type
University
Name
University of Canberra
Address
Country
Australia
Secondary sponsor category [1] 323990 0
Individual
Name [1] 323990 0
Julian Everett (University of Canberra)
Address [1] 323990 0
Country [1] 323990 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319806 0
University of Canberra Human Research Ethics Committee
Ethics committee address [1] 319806 0
Ethics committee country [1] 319806 0
Australia
Date submitted for ethics approval [1] 319806 0
14/06/2026
Approval date [1] 319806 0
Ethics approval number [1] 319806 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148462 0
Mr Julian Everett
Address 148462 0
University of Canberra, 11 Kirinari Street, Bruce, ACT 2617, Australia.
Country 148462 0
Australia
Phone 148462 0
+61 418633023
Fax 148462 0
Email 148462 0
Contact person for public queries
Name 148463 0
Julian Everett
Address 148463 0
University of Canberra, 11 Kirinari Street, Bruce, ACT 2617, Australia.
Country 148463 0
Australia
Phone 148463 0
+61 418633023
Fax 148463 0
Email 148463 0
Contact person for scientific queries
Name 148464 0
Julian Everett
Address 148464 0
University of Canberra, 11 Kirinari Street, Bruce, ACT 2617, Australia.
Country 148464 0
Australia
Phone 148464 0
+61 418633023
Fax 148464 0
Email 148464 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Studies exploring new research questions
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Journal publication or its supplementary materials: It is proposed that all data for trial will be available as supplementary material

• Email of trial custodian, sponsor or committee: Primary investigator email address ([email protected])

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    Participant Information Form - Physta Trial (1).docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.